KB-1047

Fremanezumab

×
Please enable JavaScript in your browser to complete this form.
12081
Home » Fremanezumab

Background of Fremanezumab

Fremanezumab, formerly known as TEV-48125, is a fully humanized immunoglobulin G2 monoclonal antibody that potently and selectively binds to calcitonin gene-related peptide (CGRP), thereby preventing its binding to receptors, indicated for the prevention of episodic or chronic migraine in adults.

Specifications

Catalog NumberKB-1047
Antibody NameFremanezumab
IsotypeHuman IgG2, kappa
FC MuationsA330S/P331S
TargetCGRP
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008.
  2. Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122.
Please enable JavaScript in your browser to complete this form.